Copy to clipboard 
The Mediliant Group announced Matt Burba as its new CEO. His leadership is expected to play an important factor in the company’s expansion.
Burba has over 18 years of leadership experience in the medical contract manufacturing market, most of them at Orchid Orthopedic Solutions, where he was COO before exiting the company in 2020. He brings a wide range of skills and discipline that will further strengthen the Mediliant Group’s leadership team. Mediliant noted Burba’s proven track record of leadership, sales growth through mergers and acquisitions, and organic development through his high performance in prioritizing customer needs.
“I’m excited to join Mediliant as we grow into a leading global player in the spine, trauma and extremities contract manufacturing market,” Burba said. “We have built a strong platform and expect to accelerate our strategy of creating partnerships to deliver high quality, complex implant solutions with unparalleled customer service. We will continue to add best-in-class companies that provide new and interesting technical capabilities, technologies and geographies in order to be able to better serve our customers.”
Mediliant reported it has strategic growth plans that will focus on speed and helping customers get their products first to market. The company’s goals include improving velocity on the shop floor and aiming to be the most responsive partner for its customers.
The Switzerland-based company has expanded its presence in recent years, especially in the U.S. It acquired Medical Device & Implants in 2020 and CTE Solutions in 2021.
Ekkio Capital, the Mediliant Group’s main shareholder, is committed to accelerating the company’s growth and recommended Burba as the top candidate for the CEO position.
“We are proud to welcome Matt Burba as CEO of the Mediliant Group,” Ekkio Capital President Jean-Marc Sceo said. “His background and success will be key to achieving our goals for Mediliant over the coming years.”
